Fresenius SE & Co. KGaA Q2 2026 Earnings Recap

Fresenius shares jumped 5.2% post-earnings on raised full-year core EPS guidance and margin expansion, reflecting investor approval of solid earnings growth and operational leverage across its diversified healthcare platforms.

Key Takeaways

• Core EPS grew 14% at constant currency, outpacing top-line growth and driven by strong earnings progression in Fresenius Kabi and Helios.
• EBIT increased 10% on a constant currency basis, with group EBIT margin improving 60 basis points to 12.3%.
• Return on invested capital (ROIC) strengthened to approximately 7%, about 200 basis points above 2022 post-transformation levels.
• Kabi delivered 12% organic growth with margins near 18%, benefiting from scaling innovation-led growth vectors in biopharma, nutrition, and MedTech.
• Helios maintained a resilient EBIT margin at 10.6% despite regulatory uncertainties, demonstrating steady operational performance in care services.